Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead Sciences saw strong sales growth in the first quarter. While sales were strong, margins took quite a substantial beating.

Gilead Sciences: A Mixed First Quarter

Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.

Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge

Gilead Sciences, Inc. (GILD) Q1 2023 Earnings Call Transcript.

Gilead Sciences, Inc. (GILD) Q1 2023 Earnings Call Transcript

Gilead Sciences (GILD) came out with quarterly earnings of $1.37 per share, missing the Zacks Consensus Estimate of $1.63 per share. This compares to earnings of $2.12 per share a year ago.

Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates

Gilead Sciences Inc. on Thursday cut one of its profit forecasts and reported first-quarter profit that missed expectations, with weaker demand for its COVID-19 drug weighing on results, sending shares lower in after-hours trade.

Gilead shares fall after mixed results, as weaker COVID-19 drug remand weighs

Gilead Sciences reported mixed first-quarter financial results on Thursday afternoon, as sales of its cancer and HIV drugs rose, while sales of its Covid-19 antiviral fell.

Gilead Earnings Fall Short as Demand for Covid-19 Meds Sink

Gilead's cancer treatments beat Wall Street's quarterly forecasts on Thursday, but GILD stock will likely be hampered on light profit. The post Gilead Posts Bullish Cancer Drug Sales, But Profit Questions Linger appeared first on Investor's Business Daily.

Gilead Posts Bullish Cancer Drug Sales, But Profit Questions Linger

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2023. “Gilead's track record of strong commercial and clinical execution continued through the first quarter of 2023. A 15% year-over-year revenue increase reflects growth in each of our core areas,” said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. “Biktarvy outperformed once again, and Oncology revenue increased 59% year-over-year, drive.

Gilead Sciences Announces First Quarter 2023 Financial Results

Pfizer

Pfizer and Gilead are both facing declines in demand for their coronavirus products. These big-pharma players bring in blockbuster revenue from other products, too -- and the future looks bright.

Better Buy: Pfizer vs. Gilead

AbbVie

Bristol-Myers

Eli Lilly

Merck

Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.

Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Biotech stocks for your late-April 2023 watchlist.

3 Biotech Stocks To Watch Today

Humana

Johnson & Johnson

Moderna

UnitedHealth Group

The United States healthcare system includes two sectors: public endeavors like Medicare and Medicaid and private health insurance companies. Healthcare stocks represent a significant section of the U.S. economy, with many medical companies included in indexes like the S&P 500.

6 Best Healthcare Stocks to Buy Right Now

The Federal Reserve's recent interest rate hikes mean banks charge much higher interest rates for loans. The interest on loans can be considered the price of borrowing more money.

3 Cash-Rich Biotech Stocks to Bet on for the Long Haul

Gilead Sciences is a leader in HIV treatment and has an improving oncology business. Pfizer's recent acquisitions and upcoming drug launches will help make up for its slowing coronavirus business.

2 Excellent Dividend Stocks to Buy for Less Than $100

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.

Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

High volatility means higher-than-normal option premiums, which can be great for option sellers. The post Get Income On Gilead Stock, Or Buy It At A Discount With This Option Trade appeared first on Investor's Business Daily.

Get Income On Gilead Stock, Or Buy It At A Discount With This Option Trade

Brookfield Infrastructure Partners L.P.

Conagra Brands

Crown Castle International

JPMorgan Chase & Co

W. P. Carey

Watsco

Strong quantitative screens will show investors a variety of growth stocks to buy. For example, StockRover is a screening service that scores stocks on three key metrics.

Strong Quant Screens Say These 7 Growth Stocks Are a Buy

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from several COVID-19 clinical and real-world evidence studies being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). A Phase 3 clinical study demonstrated that Veklury® (remdesivir) was generally well tolerated in people with moderate to severe renal impairment.

Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2023 financial results will be released on Thursday, April 27, 2023 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2023 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.

Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023

Amgen

Novartis

Sanofi

Walgreens

First-quarter earnings kick off in a big way on Friday with the major banks posting their results.

Why 7 of the Highest-Yielding ‘Strong Buy' Health Care Stocks Are the Absolute Best 2023 Buys

Gilead is predicting increased earnings per share this year. The company has had several key FDA approvals in recent months.

Could Gilead Sciences Stock Help You Become a Millionaire?

Archer-Daniels-Midland Company

Aflac

Allegion

Broadcom

Becton, Dickinson and Co.

Dover

Con Ed

Embecta Corp

Emerson Electric

W.W. Grainger

Kraft Heinz

Kontoor Brands Inc

LyondellBasell Industries

McDonald's

Microsoft

PepsiCo

Southern Company

Southern Co 5.25 % Notes 2017-01.12.77 Global Series 2017B

T. Rowe Price Group

The system is clearly broken, and has been for a while; however, I could find comfort in one thing, my dividends. Four figures in a month is a win in my book. Earning $1,893.81 represents 12.6% year over year increase in passive income.

DivHut Portfolio Update: March 2023

Gilead Sciences, Inc. ended 2022 on a solid note. The 2023 guidance (ex-Covid-19 contribution) feels a touch light.

News for Gilead Sciences Stock (GILD)